New safety and efficacy evidence for mitochondrial donation revealed

June 08, 2016

A new IVF-based technique is likely to lead to normal pregnancies and reduce the risk that babies born will have mitochondrial disease, according to researchers at the Wellcome Trust Centre for Mitochondrial Disease at Newcastle University.

Published today in the journal Nature, scientists report the first in-depth analysis of human embryos created using a new technique designed to reduce the risk of mothers passing on mitochondrial disease to their children, which is debilitating and often life-limiting.

The new technique, called "early pronuclear transfer", involves transplanting the nuclear DNA from a fertilised egg into a donated egg, which contains healthy mitochondria, on the day of fertilisation.

Today researchers, in a study involving over 500 eggs from 64 donor women, publish results that indicate that the new procedure does not adversely affect human development and will greatly reduce the level of faulty mitochondria in the embryo. Their results suggest that the technique will lead to normal pregnancies whilst also reducing the risk of babies having mitochondrial disease.

The results of this study will be considered by the Human Fertilisation and Embryology Authority's (HFEA) Expert Scientific Panel. The HFEA will ultimately decide whether to issue the first licence to a clinic. A licensed clinic would allow couples affected by mitochondrial disease to have the choice of whether to use pronuclear transfer to try and have healthy children.

Professor Mary Herbert, senior author of the study, said: "Having overcome significant technical and biological challenges, we are optimistic that the technique we have developed will offer affected women the possibility of reducing the risk of transmitting mitochondrial DNA disease to their children."

Extensive studies conducted in collaboration with researchers from University of Oxford and the Francis Crick Institute indicated that embryos created using the new technique are indistinguishable from those created by conventional IVF. Analysis of thousands of genes in single cells detected no difference between the two types of embryos. There was also no increase in chromosomal abnormalities, which can cause miscarriage and birth defects. These findings provide reassurance that the new procedure does not have a harmful effect on early embryonic development.

The research findings also indicate that the new technique will result in a minimal amount (less than 2%) carryover of disease-causing mitochondrial DNA to the embryos. The importance of keeping carryover to a minimum is highlighted by studies on embryonic stem cell lines. The team found that one of five stem cell lines derived from embryos created using the new technique, showed an increase in the percentage of mitochondrial DNA carryover. While stem cells are very different from embryos, the observation raises the possibility that faulty mitochondrial DNA may persist in some cases. However, the research team is optimistic that the new technique will be effective in reducing the risk of disease in children of affected women.

A further important finding of the study is that the technique will work best if patient (rather than donor) eggs are frozen. It will therefore be possible for affected women to have their eggs frozen for future use. This is likely to increase the success of the treatment by helping to avoid the decline in egg quality as women get older.

Professor Doug Turnbull, Director of the Centre for Mitochondrial Research, and co-author of the paper said: "This study using normal human eggs is a major advance in our work towards preventing transmission of mitochondrial DNA disease. The key message is that we have found no evidence the technique is unsafe. Embryos created by this technique have all the characteristics to lead to a pregnancy."

He added: "Our studies on stem cells does express a cautionary note that it might not be 100% efficient in preventing transmission, but for many women who carry these mutations the risk is far less than conceiving naturally."

In the event of a positive outcome from the Expert Panel, the team at Newcastle Fertility Centre, which is part of the Newcastle Hospitals NHS Foundation Trust, will submit an application for an HFEA license to offer pronuclear transfer to women at high risk of transmitting mitochondrial DNA disease to their children. The team is also working to secure the necessary funding to be able to offer clinical treatments on the NHS.

Professor Herbert said: "Our ongoing research is focussed on refining the techniques to further reduce the risk of transmitting disease."

She added: "I would also like to thank the women who donated eggs for this research. It would not have been possible to do this work without their help."

Dr Beth Thompson, Senior Policy Advisor at the Wellcome Trust said: "This study adds to the extensive body of evidence built up over the past ten years suggesting that mitochondrial replacement therapy is not unsafe. The results bring the UK closer to being able to offer mitochondrial replacement technique to couples affected by mitochondrial disease. The UK's strong regulatory system will now kick in to decide whether there is enough evidence that this technique is safe enough to be a good choice for families.

"Ultimately, couples affected by mitochondrial disease will be the best placed to decide whether the new technique is right for them, with advice from their doctors."
-end-
NOTES TO EDITORS

Reference

'Towards clinical application of pronuclear transfer to prevent mitochondrial DNA disease' by L.A. Hyslop et al is published online in Nature today (Wed 8 June).

To access the paper after the embargo has lifted please use this link: http://dx.doi.org/10.1038/nature18303

Contact
Hannah Isom
Senior Media Officer
Wellcome Trust
E: h.isom@wellcome.ac.uk
T: +44 (0)20 7611 8898

Helen Rae and Karen Bidewell
Media Relations Managers
Newcastle University
E: press.office@ncl.ac.uk
T: +444 (0)191 208 7850

About the Wellcome Trust Centre for Mitochondrial Research

The Wellcome Trust Centre for Mitochondrial Research is an internationally recognised centre of excellence. We aim to make a major difference to the lives of patients with disease caused by mitochondrial dysfunction. We will achieve this by integrating international quality research with training excellent young scientists and engaging with policy makers, our patients and the public. http://www.newcastle-mitochondria.com/

Wellcome Trust

Related Stem Cells Articles from Brightsurf:

SUTD researchers create heart cells from stem cells using 3D printing
SUTD researchers 3D printed a micro-scaled physical device to demonstrate a new level of control in the directed differentiation of stem cells, enhancing the production of cardiomyocytes.

More selective elimination of leukemia stem cells and blood stem cells
Hematopoietic stem cells from a healthy donor can help patients suffering from acute leukemia.

Computer simulations visualize how DNA is recognized to convert cells into stem cells
Researchers of the Hubrecht Institute (KNAW - The Netherlands) and the Max Planck Institute in Münster (Germany) have revealed how an essential protein helps to activate genomic DNA during the conversion of regular adult human cells into stem cells.

First events in stem cells becoming specialized cells needed for organ development
Cell biologists at the University of Toronto shed light on the very first step stem cells go through to turn into the specialized cells that make up organs.

Surprising research result: All immature cells can develop into stem cells
New sensational study conducted at the University of Copenhagen disproves traditional knowledge of stem cell development.

The development of brain stem cells into new nerve cells and why this can lead to cancer
Stem cells are true Jacks-of-all-trades of our bodies, as they can turn into the many different cell types of all organs.

Healthy blood stem cells have as many DNA mutations as leukemic cells
Researchers from the Princess Máxima Center for Pediatric Oncology have shown that the number of mutations in healthy and leukemic blood stem cells does not differ.

New method grows brain cells from stem cells quickly and efficiently
Researchers at Lund University in Sweden have developed a faster method to generate functional brain cells, called astrocytes, from embryonic stem cells.

NUS researchers confine mature cells to turn them into stem cells
Recent research led by Professor G.V. Shivashankar of the Mechanobiology Institute at the National University of Singapore and the FIRC Institute of Molecular Oncology in Italy, has revealed that mature cells can be reprogrammed into re-deployable stem cells without direct genetic modification -- by confining them to a defined geometric space for an extended period of time.

Researchers develop a new method for turning skin cells into pluripotent stem cells
Researchers at the University of Helsinki, Finland, and Karolinska Institutet, Sweden, have for the first time succeeded in converting human skin cells into pluripotent stem cells by activating the cell's own genes.

Read More: Stem Cells News and Stem Cells Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.